Nilai Dipunlarasaken Utang lan Kas: MIRA Pharmaceuticals (MIRA)

MIRA Pharmaceuticals is developing an advanced therapy system for anxiety and pain by implementing synthetic molecules with no addictive potential. However, development is being hindered by global instability, which limits investment inflows and international trials. The continuity of research and development is ensured through strictly regulated, closed raw material supply chains. Serving as the primary valuation tool, this price chart records the Enterprise Value at 15.26.

MIRA Pharmaceuticals focuses on developing innovative drugs that require significant investment. This full operational valuation of MIRA Pharmaceuticals sums the market capitalization and net debt to determine the actual cost of acquiring the business. This metric allows for the identification of hidden financial risks when searching for undervalued assets. Amid geopolitical barriers to clinical trials, this indicator reflects capital resilience. The trend of this metric confirms the issuer's ability to maintain liquidity.